Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 23 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited announced that its Typhoid Vi Conjugate Vaccine, ZyVac TCV, has received prequalification from the World Health Organisation. This prequalification allows ZyVac TCV to be eligible for purchase by United Nations procurement agencies. The vaccine is developed to immunize against Salmonella typhi infection and is manufactured at Zydus Biotech Park in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases